| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Myasthenia gravis (MG) is an autoimmune disease which caused by producing anti-ACh-R antibody in plasma cells which was differentiated from B cells. In this study, we showed on B cell activating factor -receptor (BAFF-R) was highly expressed on CD19+ B cells in MG patients. We also evaluated the percentage of IL-10+ regulatory B (Breg) cells on B cells. In the MG patients, the frequency of Breg cells was lower than those in healthy subjects. There was a significant correlation between the expression levels of IL-10-R on B cells and the changing rate of anti ACh-R antibody titer in plasma. From these results, we suggest that BAFF attenuate to activate B cells and stimulate production of anti ACh-R antibody in MG patients. On the other hand, IL-10 affected B cells to suppress the secretion of the autoantibody. In conclusion, induction of peripheral immune tolerance would be useful for MG patients by suppression of BAFF production and induction of IL-10.
|
